ArticleChinese medical journal pulmonary and critical care medicine2025
Burden of chronic obstructive pulmonary disease and risk factors in China from 1990 to 2021: Analysis of global burden of disease 2021.
Article in Chinese medical journal pulmonary and critical care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The patient-level economic burden of COPD in China: a systematic review of determinants and consequences.Frontiers in public health · 2026Pooled it
- Trial
- WeChat-assisted strategies for personalized health management in patients with AECOPD: A randomized controlled trial.PloS one · 2025Trial
- LungGPT: A unified multimodal system for interpretable diagnosis and clinical decision support of respiratory diseases.Cell reports. Medicine · 2026Article
- Associations between body mass index and peak expiratory flow rate and the mediating role of hand grip strength: evidence from CHARLS.Clinics (Sao Paulo, Brazil) · 2026Article
- Primary Care Integrated Management of chronic obstructive pulmonary disease (PRIM-COPD): study protocol for a cluster-randomised controlled trial.BMJ open respiratory research · 2026Article
- UBE2M deficiency in alveolar macrophages promotes emphysema through HIF-2α/MMP12 axis.Chinese medical journal pulmonary and critical care medicine · 2026Article
- Article
- Incidence of acute exacerbation and its related factors among chronic obstructive pulmonary disease patients aged 40 years and older in China.Chinese medical journal pulmonary and critical care medicine · 2026Article
- Lung function trajectories and exacerbation risks in preserved ratio impaired spirometry (PRISm) patients.Scientific reports · 2026Article
- Prior pulmonary tuberculosis deteriorated all-cause mortality in AECOPD patients after discharge.Scientific reports · 2026Article
- Gender Divergence in COPD Phenotypes and Narrowing Urban-Rural Diagnostic Gaps: A Surveillance Study in Chongqing, China, 2020-2024.International journal of chronic obstructive pulmonary disease · 2026Article
- Association of C-Reactive Protein-Triglyceride Glucose Index With Chronic Obstructive Pulmonary Disease: Results From the NHANES and CHARLS Cohorts.Mediators of inflammation · 2026Article
- Low sRAGE Level is Associated with Increased Future Exacerbation Risk in Mild-to-Moderate COPD and Patients with Chronic Bronchitis Symptoms.International journal of chronic obstructive pulmonary disease · 2026Observational
- Irisin, BMI, and SII as Predictors of Frequent Acute Exacerbations in COPD: Development of a Predictive Nomogram.International journal of chronic obstructive pulmonary disease · 2026Observational
- Residential Green and Blue Space, the Natural Environment, Genetic Susceptibility, and Incident COPD.International journal of chronic obstructive pulmonary disease · 2026Article
- The Multidimensional Burden of COPD in China: A Propensity Score-Matched Comparison with Other Prevalent Non-Communicable Diseases.International journal of chronic obstructive pulmonary disease · 2026Article
- Ironing out COPD: ferroptosis-driven immune dysregulation, metabolic rewiring, and precision therapeutic opportunities.Frontiers in immunology · 2026Review
- The Association Between Stomach Disease and Chronic Obstructive Pulmonary Disease: A Cross-Sectional Analysis of the 2018 China Health and Retirement Longitudinal Study (CHARLS).International journal of chronic obstructive pulmonary disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a common chronic disease that imposes tremendous burdens on the general populations in China and other countries worldwide. A comprehensive understanding of the contemporary epidemiological landscape of COPD is crucial for formulating effective prevention and control strategies. This study was designed to systematically evaluate the temporal trends in COPD burden and its associated risk factors in China over recent decades, providing evidence-based insights for targeted interventions. Methods: We conducted a comprehensive analysis of the Global Burden of Disease (GBD) 2021 dataset to systematically evaluate COPD epidemiology in China from 1990 to 2021. Our study quantified key disease burden indicators including incident cases, prevalent cases, deaths, and disability-adjusted life years (DALYs), along with their corresponding crude rates and age-standardized rates, while examining their temporal trends. Furthermore, we stratified these metrics by demographic characteristics (sex and age groups) and assessed the population attributable fractions of major risk factors for COPD in the Chinese population. Results: In 2021, China had an estimated 4.43 (95 % uncertainty interval [UI]: 4.01-4.86) million incident COPD cases and 50.59 (95 % UI: 44.98-57.12) million prevalent cases, accounting for nearly one-quarter of COPD prevalent cases worldwide. The crude COPD incidence and prevalence rates in China were 311.68 (95% UI: 281.75-341.62) per 100,000 and 3555.69 (95% UI: 3161.20-4014.55) per 100,000, respectively. Nearly 1.29 (95 % UI: 1.04-1.54) million individuals died from COPD, representing 10.99 % of deaths in China, and the crude mortality rate was 90.35 (95 % UI: 73.43-108.23) per 100,000. The DALYs were estimated at 23.64 (95 % UI: 20.00-27.92) million person years and the crude DALYs rate was 1661.60 (95 % UI: 1405.64-1962.54) per 100,000. The age-specific COPD incidence and prevalence rates increased substantially at 40 years of age and continued to rise thereafter. The mortality and DALY rates increased tremendously in elderly population. Sex disparities existed in the mortality and DALY rates, with both being markedly higher in men than in women, particularly among older adults aged >60 years, indicating non-optimal disease management in this population subgroup. Smoking was the leading risk factor for COPD deaths and DALYs, followed by particulate matter pollution and occupational exposure. The age-standardized rates for all metrics decreased substantially from 1990 to 2021, especially the mortality and DALY rates with decreases of 68.40 % and 68.13 %, respectively. Nevertheless, the numbers of incident and prevalent COPD cases increased, with both having doubled in 2021 compared with those in 1990. Conclusions: While the age-standardized rates for COPD incidence, prevalence, mortality, and DALYs decreased over the three decades, the number of individuals with COPD continued to rise, imposing an overwhelming burden on the Chinese population. The rapidly aging general population and population growth might be driving forces. Elderly men were a high-risk population subgroup for COPD deaths and poor quality of life. The disease burden was primarily attributed to smoking and particulate matter pollution, highlighting a need for effective preventive measures and better disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.